Omega-3 Carboxylic Acids (Epanova®): A Review of Its Use in Patients with Severe Hypertriglyceridemia

@article{Blair2014Omega3CA,
  title={Omega-3 Carboxylic Acids (Epanova{\textregistered}): A Review of Its Use in Patients with Severe Hypertriglyceridemia},
  author={Hannah A. Blair and Sohita Dhillon},
  journal={American Journal of Cardiovascular Drugs},
  year={2014},
  volume={14},
  pages={393-400}
}
Omega-3 carboxylic acids (Epanova®) [OM3-CA] is the first free fatty acid form of long-chain marine omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid being the most abundant) to be approved by the US FDA as an adjunct to diet to lower triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL). Oral OM3-CA has greater bioavailability than ethyl ester forms of omega-3 and, unlike omega-3 acid ethyl esters, does not require co-ingestion of a high-fat meal, as… 

Do we need ‘new’ omega-3 polyunsaturated fatty acids formulations?

There is the need to understand if long-term PUFA supplementation could increase the efficacy of the already-available evidence–based therapies for cardiovascular disease prevention and for the management of the diseases where the use of PUFA could have a possible improving effect.

Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease

The evidence shows that Ω-3 fatty acids have a beneficial effect on CVD through reprogramming of TRL metabolism, reducing inflammatory mediators (cytokines and leukotrienes), and modulation of cell adhesion molecules.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia

Icosabutate was efficacious in lowering non-HDL-C and other biomarkers of cardiovascular risk and was generally well tolerated in patients with persistent hypertriglyceridemia despite statin therapy.

Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial

The timing of OM3-CA administration relative to food intake influences the systemic bioavailability of EPA and DHA in healthy Japanese male subjects.

Evaluation of the Efficacy of Omega-3 Fatty Acids Formulations in the Lipopolysaccharide-Induced Acute Lung Inflammation Rat Model

Preclinical data suggest that O3FA formulations should be further investigated as treatments in lung inflammation and thrombosis related lung disorders, including asthma, chronic obstructive pulmonary disease, lung cancer and acute respiratory distress like COVID-19.

Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

This review presents the most recent advances in hypertriglyceridemia treatment and critically comments on apolipoprotein C-III inhibitors, angiopoietin-like 3 inhibitors, alipogene tiparvovec, pradigastat, pemafibrate and novel formulations of omega-3 fatty acids.

Role of Omega-3 Fatty Acids in Metabolic Syndrome

This chapter will focus on reviewing randomized, controlled trials that evaluate the effects of supplementation with marine-derived EPA and DHA on weight loss, insulin sensitivity, lipid metabolism, blood pressure, and inflammation in overweight/obese subjects with MetS characteristics.

Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders

This current review shows that the consumption of unsaturated fatty acids, MUFA, and PUFA; and especially EPA and DHA, which can be applied as food supplements, may promote effects on glucose and lipid metabolism, as well as on metabolic inflammation, gut microbiota, and hepatic metabolism.

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega‐3‐Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single‐Blind, Randomized, Placebo‐Controlled Trial

Overall, OM3‐CA was well tolerated in healthy Japanese subjects and the pharmacokinetic profiles of EPA and DHA after administration of OM3-CA were comparable between Japanese and white subjects.

References

SHOWING 1-10 OF 20 REFERENCES

Overview of omega-3 Fatty Acid therapies.

The REDUCE-IT study is being conducted to evaluate the effect of the combination of IPE and statins on cardiovascular outcomes in high-risk patients.

Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia

P-OM3 are effective in reducing triglycerides by ∼ 30% in this population and are likely to be combined with other drugs (e.g., statins) to treat combined dyslipidemia.

Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.

Epanova is a novel ω-3 free fatty acid formulation, developed to maximize eicosapentenoic acid and docosahexenoic acids bioavailability with low-fat diets, suggesting a potential therapeutic advantage compared with ω -3-acid ethyl esters in the treatment of patients with hypertriglyceridemia.

Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.

  • M. Davidson
  • Biology
    The American journal of cardiology
  • 2006

Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study

The bioavailability of the FFA forms of EPA and DHA in Epanova are significantly greater than the bioavailability from the EE forms present in Lovaza under low-fat dietary conditions normally recommended for patients with cardiovascular disease, and may lead to improved triglyceride-lowering in patients with hypertriglyceridemia.